Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
Enzyme replacement therapy (ERT) has been widely used for the treatment of Fabry disease, a rare X-linked recessive disorder due to absent or reduced activity of lysosomal enzyme α-galactosidase A. It is still unclear why some patients under ERT show disease progression typically with renal, cardiovascular and cerebrovascular dysfunctions. Here, we investigated the involvement of drug absorption, distribution, metabolism, and excretion gene variants in response variability to ERT, genotyping 37 patients with the Affymetrix Drug Metabolizing Enzyme and Transporters (DMET) Plus microarray. We found three single nucleotide polymorphisms in human alcohol dehydrogenase (ADH)4 gene (rs1126670, rs1126671, rs2032349) and one in ADH5 gene (rs2602836) associated with disease progression (p < 0.05). Our data provide a basic tool for identification of patient with ERT non-response risk that may represent a framework for personalized treatment of this rare disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 64 vom: 08. Dez., Seite 107558-107564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scionti, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADH genes |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.22505 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279594216 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279594216 | ||
| 003 | DE-627 | ||
| 005 | 20231225023333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.22505 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0931.xml |
| 035 | |a (DE-627)NLM279594216 | ||
| 035 | |a (NLM)29296186 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scionti, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic variants associated with Fabry disease progression despite enzyme replacement therapy |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Enzyme replacement therapy (ERT) has been widely used for the treatment of Fabry disease, a rare X-linked recessive disorder due to absent or reduced activity of lysosomal enzyme α-galactosidase A. It is still unclear why some patients under ERT show disease progression typically with renal, cardiovascular and cerebrovascular dysfunctions. Here, we investigated the involvement of drug absorption, distribution, metabolism, and excretion gene variants in response variability to ERT, genotyping 37 patients with the Affymetrix Drug Metabolizing Enzyme and Transporters (DMET) Plus microarray. We found three single nucleotide polymorphisms in human alcohol dehydrogenase (ADH)4 gene (rs1126670, rs1126671, rs2032349) and one in ADH5 gene (rs2602836) associated with disease progression (p < 0.05). Our data provide a basic tool for identification of patient with ERT non-response risk that may represent a framework for personalized treatment of this rare disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADH genes | |
| 650 | 4 | |a DMET | |
| 650 | 4 | |a Fabry disease | |
| 650 | 4 | |a enzyme replacement therapy | |
| 650 | 4 | |a oxidative stress | |
| 700 | 1 | |a Di Martino, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Sestito, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Nicoletti, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Falvo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Roppa, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Arbitrio, Mariamena |e verfasserin |4 aut | |
| 700 | 1 | |a Guzzi, Pietro Hiram |e verfasserin |4 aut | |
| 700 | 1 | |a Agapito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Pisani, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Riccio, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Concolino, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pensabene, Licia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 64 vom: 08. Dez., Seite 107558-107564 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:64 |g day:08 |g month:12 |g pages:107558-107564 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.22505 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 64 |b 08 |c 12 |h 107558-107564 | ||